Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication

X
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LUTE
  • Sponsors Genentech
  • Most Recent Events

    • 30 Mar 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
    • 25 Feb 2019 Results of post-hoc analysis assessing stability of eosinophil levels from four studies (LUTE, VERSE, LAVOLTA I and LAVOLTA II) presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 18 May 2016 Results (pooled analysis of this and other two studies) assessing correlation between the change in these pharmacodynamics biomarkers and the change in FEV1 presented at the 112th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top